Revlimid Granted Approval For Multiple Myeloma In Japan – Celgene announced last week that Revlimid ^[1] (lena­lido­mide) has been approved for the treat­ment of re­lapsed and re­frac­tory multiple myeloma in com­bi­na­tion with dexamethasone ^[2] (Decadron) in Japan. Revlimid will be avail­able through Revmate, a pro­pri­e­tary distribution pro­gram. For more in­for­ma­tion, please read the Celgene ^[3] press release.

Immunomedics Doses First Multiple Myeloma Patient With Milatuzumab-Doxorubicin Combination – Immunomedics has dosed the first patient in a Phase 1/2 study of its milatuzumab-based treat­ment for multiple myeloma. This treat­ment has doxorubicin ^[4] (Adriamycin), a chemo­ther­apy drug, bound to milatuzumab, an anti­body. It will be eval­u­ated for its efficacy as a treat­ment for re­lapsed and re­frac­tory multiple myeloma patients. For more in­for­ma­tion, please see the Immunomedics ^[5] press release and the clinical trial ^[6] description.

ImmunoGen And Sanofi-Aventis Announce Beginning Of Phase 1 Trial Of Potential New Myeloma Treatment – ImmunoGen Inc. and Sanofi-Aventis announced the initiation of a Phase 1 clin­i­cal trial of SAR650984, an anti­body that targets cancer cells. In pre­clin­i­cal testing, SAR650984 was found to have anti-cancer effects, and is now being in­ves­ti­gated as a treat­ment for re­lapsed and re­frac­tory multiple myeloma as well as other blood cancers. For more in­for­ma­tion, please refer to the ImmunoGen ^[7] press release.